Results 51 to 60 of about 765 (143)

Upfront combination therapy with sildenafil and ambrisentan in patients with chronic thromboembolic pulmonary hypertension. [PDF]

J Bras Pneumol
Salibe-Filho W, Vieira TM, Leonidas Alves-Junior J, Nascimento YPP, Tatagiba LS, Fernandes CJC, Jardim CVP, Terra-Filho M, Souza R.   +8 more
europepmc   +1 more source

Therapy in diabetic dyslipidemia. [PDF]

Indian J Pharmacol
Maheswari U.
europepmc   +1 more source

Saroglitazar and vitamin E vs. lifestyle interventions in metabolic dysfunction associated steatotic liver disease: A 3-arm randomised study. [PDF]

Indian J Med Res
Tiwari AK, Singh G, Kumar V, Yadav DP, Shukla SK, Singh V, Mishra G, Tiwary NK, Anunay A, Singh D, Chaturvedi D.   +10 more
europepmc   +1 more source

Efficacy and safety of SarogLItazar as an add-on medication to Metformin and lifestyle intervention in women with PolyCystic Ovary Syndrome (SLIM-PCOS trial): study protocol for a randomized, open-label, parallel group clinical trial. [PDF]

Trials
Mittal N, Singhal S, Mittal R.
europepmc   +1 more source

Pharmacokinetic assessment of elexacaftor/tezacaftor/ivacaftor and their metabolites in maternal blood, cord blood, the neonate, and breastmilk of a cystic fibrosis carrier mother/affected fetus dyad. [PDF]

J Cyst Fibros
Sinkey RG, Garcia B, Fowler CM, Krick S, Ryan KJ, Acosta EP, Guimbellot JS.   +6 more
europepmc   +1 more source

Effect of nanoliposomal gamma-oryzanol on cryosurvival, oxidative balance, and fertility of frozen-thawed ram spermatozoa. [PDF]

Sci Rep
Abbasi R, Farhadi R, Varjovi SG, Najafi A.   +3 more
europepmc   +1 more source

Saroglitazar for non-obese metabolic-dysfunction associated steatotic liver disease (MASLD): An open-label randomised controlled trial. [PDF]

Indian J Med Res
Bhagat N, De A, Duseja A, C P G, Kumar M, Mehta M, Taneja S, Sahni N, Singh V.   +8 more
europepmc   +1 more source

Impact of Elexacaftor-Tezacaftor-Ivacaftor on Gastrointestinal Symptoms, Intestinal Ultrasound, and Pancreatic Stiffness in Cystic Fibrosis. [PDF]

Clin Transl Gastroenterol
Fraquelli M, Piagnani A, Corti F, Lanfranchi C, Casazza G, Colombo C.   +5 more
europepmc   +1 more source

Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocol. [PDF]

BMJ Open
He K, Chen F, Shao R, Jiang W, Gu W, Huang Z, Gan Y, Wang Y, Wu H, Zhao Y, Zhang B, Gao L, Yan X, Yao C, Shen C, Ji P, Wei J, Bian Y, Lu Y, Abuduaini A, Liu L, Li H.   +21 more
europepmc   +1 more source

Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.

Health Technol Assess
Edwards SJ, Farrar BG, Ennis K, Downes N, Wakefield V, Mackenzie I, Walters A, Jhita T.   +7 more
europepmc   +1 more source